Melicent Peck, MD, PhD
Attending Physician
Medicine
School of Medicine
Melicent Peck is a board-certified infectious diseases physician. She completed her MD/PhD training and internal medicine residency at Stanford University, infectious diseases fellowship at UCSF, and the Advanced Training in Clinical Research certificate at UCSF.
Show full bio (46 words) Hide full bio
She currently leads the early clinical development of novel antibiotics against multi-drug resistant bacteria and contributes to strategies to ensure that new antibiotics reach patients. She also leads the early clinical development of new immunotherapies. She is an attending physician at the UCSF Infectious Diseases Clinic.
Awards
Show all (1) Hide
- CROI Young Investigator Award, 2014
Education & Training
Show all (6) Hide
- Certificate in Clinical Research Epidemiology and Biostatistics UCSF 2014
- Fellowship Infectious Diseases UCSF 2013
- Residency Internal Medicine Stanford University 2010
- M.D. Medicine Stanford University 2007
- Ph.D. Biological Sciences Stanford University 2002
- BA, BS Biochemistry University of California, Berkeley
Interests
Show all (5) Hide
- Host-microbe interactions
- Clinical trials
- Infectious diseases
- Drug development
- HIV immunopathogenesis
Publications (17)
Top publication keywords:
Sinorhizobium melilotiFlavonoidsChemokine CCL2Bacterial ProteinsGene Expression Regulation, BacterialAnti-Bacterial AgentsLuteolinDNA-Directed RNA PolymerasesOseltamivirTranscription FactorsInfluenza A virusStaphylococcal InfectionsInfluenza, HumanTranscriptional ActivationTrans-Activators
-
Early plasma angiopoietin-2 is prognostic for ARDS and mortality among critically ill patients with sepsis.
Critical care (London, England) 2023 Rosenberger CM, Wick KD, Zhuo H, Wu N, Chen Y, Kapadia SB, Guimaraes A, Chang D, Choy DF, Chen H, Peck M, Sullivan KM, Ke S, Jauregui A, Leligdowicz A, Sinha P, Gomez AD, Kangelaris KN, Delucchi K, … -
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial.
Critical care medicine 2022 Waters M, McKinnell JA, Kalil AC, Martin GS, Buchman TG, Theess W, Yang X, Lekkerkerker AN, Staton T, Rosenberger CM, Pappu R, Wang Y, Zhang W, Brooks L, Cheung D, Galanter J, Chen H, Mohan D, Peck MC… -
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection.
Open forum infectious diseases 2021 Lim JJ, Dar S, Venter D, Horcajada JP, Kulkarni P, Nguyen A, McBride JM, Deng R, Galanter J, Chu T, Newton EM, Tavel JA, Peck MC -
Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.
Journal of clinical pharmacology 2020 Deng R, She G, Maia M, Lim JJ, Peck MC, McBride JM, Kulkarni P, Horn P, Castro A, Newton E, Tavel JA, Hanley WD -
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection.
Antimicrobial agents and chemotherapy 2020 Lim JJ, Nilsson AC, Silverman M, Assy N, Kulkarni P, McBride JM, Deng R, Li C, Yang X, Nguyen A, Horn P, Maia M, Castro A, Peck MC, Galanter J, Chu T, Newton EM, Tavel JA
Show all (12 more) Hide
-
Risk stratification biomarkers for Staphylococcus aureus bacteraemia.
Clinical & translational immunology 2020 Cao Y, Guimaraes AO, Peck MC, Mayba O, Ruffin F, Hong K, Carrasco-Triguero M, Fowler VG, Maskarinec SA, Rosenberger CM -
A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers.
Antimicrobial agents and chemotherapy 2019 Peck M, Rothenberg ME, Deng R, Lewin-Koh N, She G, Kamath AV, Carrasco-Triguero M, Saad O, Castro A, Teufel L, Dickerson DS, Leonardelli M, Tavel JA -
A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Guimaraes AO, Cao Y, Hong K, Mayba O, Peck MC, Gutierrez J, Ruffin F, Carrasco-Triguero M, Dinoso JB, Clemenzi-Allen A, Koss CA, Maskarinec SA, Chambers HF, Fowler VG, Baruch A, Rosenberger CM -
Prognostic Power of Pathogen Cell-Free DNA in Staphylococcus aureus Bacteremia.
Open forum infectious diseases 2019 Guimaraes AO, Gutierrez J, Maskarinec SA, Cao Y, Hong K, Ruffin F, Carrasco-Triguero M, Peck MC, Fowler VG, Baruch A, Rosenberger CM -
Sustained Circulating Bacterial Deoxyribonucleic Acid Is Associated With Complicated Staphylococcus aureus Bacteremia.
Open forum infectious diseases 2019 Gutierrez J, Guimaraes AO, Lewin-Koh N, Berhanu A, Xu M, Cao Y, Kim J, Yan D, Chang JK, Dinoso JB, Koss CA, Clemenzi-Allen A, Chambers HF, Peck MC, Baruch A, Rosenberger CM -
Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals.
PLoS pathogens 2014 Klatt NR, Bosinger SE, Peck M, Richert-Spuhler LE, Heigele A, Gile JP, Patel N, Taaffe J, Julg B, Camerini D, Torti C, Martin JN, Deeks SG, Sinclair E, Hecht FM, Lederman MM, Paiardini M, Kirchhoff F,… -
Isolation and characterization of mutant Sinorhizobium meliloti NodD1 proteins with altered responses to luteolin.
Journal of bacteriology 2013 Peck MC, Fisher RF, Bliss R, Long SR -
Diverse flavonoids stimulate NodD1 binding to nod gene promoters in Sinorhizobium meliloti.
Journal of bacteriology 2006 Peck MC, Fisher RF, Long SR -
The RNA polymerase alpha subunit from Sinorhizobium meliloti can assemble with RNA polymerase subunits from Escherichia coli and function in basal and activated transcription both in vivo and in vitro.
Journal of bacteriology 2002 Peck MC, Gaal T, Fisher RF, Gourse RL, Long SR -
Luteolin and GroESL modulate in vitro activity of NodD.
Journal of bacteriology 2002 Yeh KC, Peck MC, Long SR -
Nucleotide sequence and predicted functions of the entire Sinorhizobium meliloti pSymA megaplasmid.
Proceedings of the National Academy of Sciences of the United States of America 2001 Barnett MJ, Fisher RF, Jones T, Komp C, Abola AP, Barloy-Hubler F, Bowser L, Capela D, Galibert F, Gouzy J, Gurjal M, Hong A, Huizar L, Hyman RW, Kahn D, Kahn ML, Kalman S, Keating DH, Palm C, Peck MC… -
The composite genome of the legume symbiont Sinorhizobium meliloti.
Science (New York, N.Y.) 2001 Galibert F, Finan TM, Long SR, Puhler A, Abola P, Ampe F, Barloy-Hubler F, Barnett MJ, Becker A, Boistard P, Bothe G, Boutry M, Bowser L, Buhrmester J, Cadieu E, Capela D, Chain P, Cowie A, Davis RW, …